Human IL-17A Antibody - Secukinumab Biosimilar
| Product | Unit size | Cat. code | Docs. | Qty. | Price | |
|---|---|---|---|---|---|---|
|
Anti-hIL17A-hIgG1 Human IL-17A (Secukinumab) antibody - Human IgG1 |
Show product |
100 µg 3 x 100 µg |
hil17a-mab1
|
|
Anti-human IL-17A - Secukinumab biosimilar - CAS #1229022-83-6
Binding of Anti-hIL-17A Secukinumab
InvivoGen also offers:
Anti-hIL-17A-hIgG1 is a biosimilar antibody of Secukinumab, a human interleukin-17A (IL-17A) antibody that specifically blocks IL-17A signaling. This monoclonal antibody (mAb) is FDA-approved for treating moderate-to-severe plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis.
Anti-hIL-17A-hIgG1 comprises the variable region of Secukinumab and the IgG1 constant region of Secukinumab, mediating high effector functions.
This antibody can be used together with HEK-Blue™ IL-17 cells for screening and neutralization assays to block IL-17A signaling induced by recombinant human IL-17A (see figure).
Key features
- Each lot is functionally tested and validated.
- The complete sequence of the antibody construct has been verified.
- The absence of endotoxins is determined by the EndotoxDetect™ assay.
All InvivoGen products are for internal research use only, and not for human or veterinary use.
Figures
Specifications
Application: Neutralization assay, ELISA
Isotype: Human IgG1, kappa
Recommended isotype control: Human IgG1
Target: Human IL-17A
Species reactivity: Human
Clone: Secukinumab, AIN457, Cosentyx
Cas number: 1229022-83-6
Source: CHO cells
Production: Animal-free
Purification: Protein A
Molecular weight: 148 kDa
Physical form: Lyophilized
Formulation buffer: Sodium phosphate buffer with glycine, saccharose, and stabilizing agents
Preservative: Azide-free
Reconstitution buffer: Sterile water (not provided)
Purity: ≥ 95 %
Quality control: Each lot is functionally tested and validated.
Back to the topContents
Anti-hIL-17A-hIgG1 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:
- hil17a-mab1: 100 µg
- hil17a-mab1-03: 3 x 100 µg
Upon receipt, store lyophilized antibody at -20 °C.
The lyophilized product is stable for at least 1 year.
Avoid repeated freeze-thaw cycles.
Details
Secukinumab background
Secukinumab (AIN457), a fully human anti-hIL-17A-hIgG1 mAb, was designed to selectively target the human interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in Th17 immunity as well as in the pathogenesis of autoimmune diseases [1]. IL-17A, also known as CTLA‑8, is able to induce chemokine production, neutrophil influx, and the production of antibacterial peptides [2].
By binding IL-17A, Secukinumab prevents its interaction with the IL-17 receptor complex (IL-17RA/RC), thereby inhibiting downstream inflammatory signaling and cytokine production [2-3]. Secukinumab has demonstrated strong clinical efficacy in improving skin lesions and joint symptoms. In 2015, this first-in-class anti-IL-17A mAb was approved by the FDA for the treatment of moderate-to-severe plaque psoriasis, leading to the complete clearance of psoriatic plaques [3]. One year later, Secukinumab was also approved for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) [3]. Surprisingly, trials of Secukinumab in Crohn’s disease were terminated early due to worsening of the disease in the treatment group [2-3]. These findings agree with IL-17's supportive role in skin wound healing [2].
References:
1. Monin L. & Gaffen S.L., 2018. Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications. Cold Spring Harb Perspect Biol. 10(4).
2. Huangfu L, Li R, Huang Y, Wang S, 2023. The IL-17 family in diseases: from bench to bedside. Signal Transduct Target Ther.11;8(1):402.
3. Amatya N, Garg AV, Gaffen SL, 2017. IL-17 Signaling: The Yin and the Yang. Trends Immunol. 38(5):310-322